EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers

Giusi Bondì, Serafina Martella, Dimitrios Stylianakis iD, Alberto Terminella, Filippo Lococo iD, Alessia Ciarrocchi iD, Alfonso Fiorelli iD, Giacomo Cusumano iD

Current Oncology · 03.02.2026 · 33 (2) · 93

DOI: 10.3390/curroncol33020093 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 03.02.2026. Verfasst von Giusi Bondì und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery Unit, Policlinico-San Marco Hospital, University of Catania, 95124 Catania, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has significantly reshaped the management of malignant pleural mesothelioma (MPM), offering new therapeutic opportunities after decades in which platinum–pemetrexed chemotherapy represented the only systemic option. However, clinical benefit remains markedly heterogeneous, with outcomes strongly influenced by histologic subtype, patient characteristics, and real-world treatment conditions. Evidence from monotherapy trials has been inconsistent, whereas combination approaches—particularly nivolumab plus ipilimumab—have demonstrated improved survival compared with chemotherapy, mainly in non-epithelioid tumors. Nevertheless, real-world data consistently show lower efficacy and higher toxicity than registrational studies, especially among elderly and unselected populations. Recent translational work has highlighted the relevance of the tumor microenvironment and recurrent genomic alterations such as BAP1, NF2, and CDKN2A in shaping immune activity and potentially modulating response to immune checkpoint inhibitors. Transcriptomic signatures and circulating biomarkers—including soluble mesothelin-related peptide—have shown prognostic associations but no validated predictive value. Overall, current evidence suggests that sensitivity to immunotherapy in MPM arises from a complex interplay of genomic, immunologic, and clinical factors, and that no biomarker is yet suitable for guiding treatment decisions. Prospective studies integrating molecular and immune profiling will be essential to refine patient selection and advance toward a more rationally personalized use of immunotherapy

Schlagwörter

Stichwörter der Autor:innen

biomarkersgenomic alterationsimmune checkpoint inhibitorsimmunotherapy outcomesmalignant pleural mesotheliomatumor microenvironment

Autor:innen und Institutionen

  • Department of Thoracic Surgery Unit, Policlinico-San Marco Hospital, University of Catania, 95124 Catania, Italy.
  • Respiratory Medicine Unit, Policlinico "G. Rodolico-San Marco" University Hospital, 95123 Catania, Italy.
  • School of Medicine, University Hospital and University of Crete, 70013 Iraklion, Greece.
  • Thoracic Surgery Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
  • Department of General Thoracic Surgery, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy .
  • Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

ORCID-Profile: Dimitrios Stylianakis, Filippo Lococo, Alessia Ciarrocchi, Alfonso Fiorelli, Giacomo Cusumano

Förderung

  • European Union

Zitieren

APA

Bondì, G., Martella, S., Stylianakis, D., Terminella, A., Lococo, F., Ciarrocchi, A., Fiorelli, A., & Cusumano, G. (2026). Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers. Current Oncology, 33(2), 93. https://doi.org/10.3390/curroncol33020093

Vancouver

Bondì G, Martella S, Stylianakis D, Terminella A, Lococo F, Ciarrocchi A, et al. Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers. Current Oncology. 2026;33(2):93. doi:10.3390/curroncol33020093

BibTeX
@article{Bond2026,
  author = {Bondì, Giusi and Martella, Serafina and Stylianakis, Dimitrios and Terminella, Alberto and Lococo, Filippo and Ciarrocchi, Alessia and Fiorelli, Alfonso and Cusumano, Giacomo},
  title = {Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {2},
  pages = {93},
  doi = {10.3390/curroncol33020093}
}
Kostenlos starten →